These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1571080)

  • 1. Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
    Kleedorfer B; Poewe W
    J Neural Transm Park Dis Dement Sect; 1992; 4(2):173-8. PubMed ID: 1571080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of sustained dopaminergic stimulation.
    Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
    Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
    Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
    Eur Neurol; 1987; 27 Suppl 1():68-72. PubMed ID: 3428310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease.
    Lieberman A; Gopinathan G; Miller E; Neophytides A; Baumann G; Chin L
    Eur Neurol; 1990; 30(2):75-8. PubMed ID: 2340838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
    Steiger MJ; Stocchi F; Bramante L; Ruggieri S; Quinn NP
    Clin Neuropharmacol; 1992 Dec; 15(6):501-4. PubMed ID: 1477849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
    Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
    Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
    Poewe WH; Lees AJ; Stern GM
    Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
    Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
    Pakkenberg H; Birket-Smith E; Dupont E; Hansen E; Mikkelsen B; Presthus J; Rautakorpi I; Riman E; Rinne UK
    Acta Neurol Scand; 1976 May; 53(5):376-85. PubMed ID: 1266576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS; Covicković-Sternić N
    Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Oct; 37(10):1607-12. PubMed ID: 3658164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease.
    Friedman JH; Lannon MC
    Clin Neuropharmacol; 1989 Jun; 12(3):220-3. PubMed ID: 2743346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.
    Bulling MT; Wing LM; Burns RJ
    Aust N Z J Med; 1991 Aug; 21(4):397-400. PubMed ID: 1953526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open clinical study of Madopar HBS.
    Ludin HP
    Eur Neurol; 1987; 27 Suppl 1():73-5. PubMed ID: 3322838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
    Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
    Pacchetti C; Martignoni E; Sibilla L; Bruggi P; Turla M; Nappi G
    Eur Neurol; 1990; 30(6):319-23. PubMed ID: 2289507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.